Open an account

IDEXX Laboratories

IDXX · NASDAQ

$557.93+$2.13 (+0.38%)TodayMarket closed ·
Prev close $555.80

About IDXX

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. The company is headquartered in Westbrook, Maine and currently employs 11,000 full-time employees. The firm also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

Employees
11,000
Headquarters
Westbrook, Maine
Listed
Jun 21, 1991
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
idexx.com

IDXX key statistics

Market cap
43.95B
Price-earnings ratio
39.06
Dividend yield
—
Average volume
516.00K
Volume
439.77K
Open price
$559.14
High today
$561.83
Low today
$552.78
52 Week high
$769.98
52 Week low
$500.61

IDEXX Laboratories (IDXX) at a glance

IDEXX Laboratories (IDXX) last traded at $557.93, with a market cap of 43.95B and a price-to-earnings ratio of 39.06.

Today the stock has traded between $552.78 and $561.83. The current price is 0.9% above the day's low and 0.7% below its high.

Volume so far is 439.77K shares, in line with the average of 516.00K shares a day.

Over the past year IDEXX Laboratories has ranged from $500.61 to $769.98, and now sits 21% of the way up that range.

IDEXX Laboratories met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported $4.27 per share against an estimate of $4.02.

The average analyst price target is $723.29, 29.6% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

56%of 9 analyst ratings say Buy
  • Buy55.6%
  • Hold44.4%
  • Sell0.0%
Price target · 16 analystsAvg $723.29
Low
$477.17
Now
$557.93
High
$845.25

IDXX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 4.3% on average.

  1. Q3 FY24: reported $2.80 per share against an estimate of $2.73
  2. Q4 FY24: reported $2.62 per share against an estimate of $2.45
  3. Q1 FY25: reported $2.96 per share against an estimate of $2.91
  4. Q2 FY25: reported $3.63 per share against an estimate of $3.37
  5. Q3 FY25: reported $3.40 per share against an estimate of $3.19
  6. Q4 FY25: reported $3.08 per share against an estimate of $2.99
  7. Q1 FY26: reported $3.47 per share against an estimate of $3.47
  8. Q2 FY26: reported $4.27 per share against an estimate of $4.02

IDXX news

  • Piero Cingari

    Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average

  • Press releaseBusiness Wire

    IDEXX Laboratories to Release 2026 Third Quarter Financial Results

  • Press releasePRNewswire

    Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories

  • Press releaseBusiness Wire

    IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection

  • Press releaseBusiness Wire

    IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence

  • Press releaseBusiness Wire

    IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

  • Press releaseBusiness Wire

    IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

  • Vandana Singh

    Why Is IDEXX Laboratories Stock Gaining Tuesday?

Similar companies

Companies in the same industry as IDEXX Laboratories

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.